serum adiponectin levels in advanced-stage parkinsons disease patients帕金森病晚期患者的血清脂联素水平.pdfVIP

SAGE-Hindawi Access to Research Parkinson’s Disease Volume 2011, Article ID 624764, 6 pages doi:10.4061/2011/624764 Research Article Serum Adiponectin Levels in Advanced-Stage Parkinson’s Disease Patients Erica Cassani,1 Raffaella Cancello,1, 2 Ferruccio Cavanna,1, 3 Sabrina Maestrini,2 Anna Maria Di Blasio,2 Antonio Liuzzi,2 Gianni Pezzoli,1 and Michela Barichella1 1 Parkinson Institute, Istituti Clinici di Perfezionamento (ICP), via Bignami 1, 20126 Milan, Italy 2 Istituto Auxologico Italiano, via Zucchi 18, 20095 Cusano Milanino, Milan, Italy 3 Centro Analisi Monza (CAM), via Missori 9, 20052 Monza, Italy Correspondence should be addressed to Erica Cassani, erica.x@libero.it Received 10 January 2011; Revised 21 March 2011; Accepted 24 April 2011 Academic Editor: Francisco Grandas Copyright © 2011 Erica Cassani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Patients with advanced Parkinson’s disease (PD) experience body weight loss and reductions in the most common cardiovascular risk factors. At present, the pathogenetic mechanisms involved have not been elucidated. Increased serum concentrations of adiponectin, which possesses antiatherogenic and anti-inflammatory properties, are associated with a reduction in cardiovascular risk. The objective of this study was to determine adiponectin serum concentrations in PD patients. Thirty PD patients underwent a full nutritional status assessment, including the determination of adiponectin serum concentrations. Mean ± SD adiponectin concentrations were 9.59 ± 5.9 μg/mL (interquartile range: 5.92–12.9 μg/mL). In PD patients, adiponec